Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

1.77
-0.0700-3.80%
Post-market: 1.770.0003+0.02%19:35 EDT
Volume:2.61M
Turnover:4.66M
Market Cap:106.49M
PE:-3.14
High:1.84
Open:1.81
Low:1.76
Close:1.84
52wk High:6.73
52wk Low:1.07
Shares:60.16M
Float Shares:48.48M
Volume Ratio:0.40
T/O Rate:5.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5636
EPS(LYR):-0.5636
ROE:-58.73%
ROA:-24.95%
PB:2.41
PE(LYR):-3.14

Loading ...

Insider Makes Bold Move on Aldeyra Therapeutics Stock

TIPRANKS
·
Mar 21

Aldeyra Therapeutics Principal Financial Officer Michael Alfieri acquires USD 7,100 of common shares

Reuters
·
Mar 20

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Benzinga_recent_news
·
Mar 19

Levi & Korsinsky probes Aldeyra Therapeutics over potential securities fraud claims

Reuters
·
Mar 19

Aldeyra Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Mar 18

HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10

MT Newswires Live
·
Mar 18

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Mar 18

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Reuters
·
Mar 18

BUZZ-U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora

Reuters
·
Mar 18

Aldeyra Therapeutics Shares Hit Record Low After US FDA Declines to Approve Eye Disorder Drug, Last Down 70%

THOMSON REUTERS
·
Mar 17

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

Dow Jones
·
Mar 17

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

TIPRANKS
·
Mar 17

How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?

TIPRANKS
·
Mar 17

Aldeyra Therapeutics Shares Down 73% Premarket After US FDA Declines to Approve Eye Disorder Drug

THOMSON REUTERS
·
Mar 17

FDA issues complete response letter for Aldeyra’s reproxalap dry eye NDA

Reuters
·
Mar 17

Aldeyra Therapeutics Inc - No Safety or Manufacturing Concerns Identified in Reproxalap Nda Review

THOMSON REUTERS
·
Mar 17

Aldeyra Therapeutics Inc - FDA States Reproxalap Nda Failed to Demonstrate Efficacy for Dry Eye Disease

THOMSON REUTERS
·
Mar 17

Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

THOMSON REUTERS
·
Mar 17

Aldeyra Therapeutics Inc - to Request Type a Meeting With FDA Within 30 Days per Pdufa Goals

THOMSON REUTERS
·
Mar 17

Aldeyra Therapeutics Inc - FDA Recommends Exploring Trial Failures; No Additional Trials Requested for Reproxalap

THOMSON REUTERS
·
Mar 17